Other
Journal
About P&T Journal
Contacts:Editor:
ssherritze@medimedia.com
Advertising:
mliberti@medimedia.com
Circulation:
lgardineer@medimedia.com
Production:
wpeart@medimedia.com
Rate Card
Production Specifications
Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints
Recent Issues
April 2003
Features
Letter to the Editor
Providers to Share Data About Causes of Medical Errors
The Patient Safety and Quality Improvement Act (H.R.663) encourages providers to conduct research and gather data about the causes of medical mishaps and then share their findings with other providers.
Cheryl Servais
Pharmaceutical-Approval Update
The author reviews adalimumab for rheumatoid arthritis, alefacept for
psoriasis, and cyclosporine ophthalmic emulsion for chronic dry eye disease.
Marvin M. Goldenberg, PhD, RPh, MS
Physician Perspective
What’s Going to Happen to Brave Surgeons and Patients?
A practicing physician describes the fears that surgeons must confront when
treating high-risk patients.
Thomas Marzili, MD
Continuing Education Credit
Voriconazole: A New Triazole Antifungal Agent
The author reviews a new medication for the treatment of invasive aspergillosis, febrile neutropenia, and candidiasis.
S. Scott Sutton, PharmD
Departments
Editorial
Advocating Health for Greater Productivity and Improved Morale
Editor-in-Chief David Nash, MD, MBA, highlights a company that helps employees resolve problems with their health benefits.
David B. Nash, MD, MBA
Spotlight
Welcome, Dr. Greengold
Dr. Nancy Greengold is the newest addition to P&T’s Editorial Board.
Sonja Sherritze
Medication Errors
“Rule of 6” Not Optimal for Patient Safety
Matthew Grissinger discusses the “rule of 6” shortcut and its tendency to lead to errors.
Matthew Grissinger
Prescription Washington
The Medicare Mess and Congressional Chaos
Stephen Barlas describes the confusion surrounding President Bush’s proposed Medicare drug benefit.
Stephen Barlas
Drug News
New Drugs/Drug News
The latest information about approvals, indication changes, industry updates, and news from the FDA
Drug Forecast
Aripiprazole: A New Antipsychotic Agent with a Unique Mechanism of Action
Dr. Vanni and Mr. Inzerillo review aripiprazole, a new antipsychotic medication.
Nicholas Vanni, PharmD, and Michael T. Inzerillo, MBA
Use of Antifungal Therapies in Patients with Sepsis
